Chemo-immunotherapy combination after PD-1 inhibitor failure improves clinical outcomes in metastatic melanoma patients

Management of PD-1 blockade resistance in metastatic melanoma (MM) remains challenging. Immunotherapy or chemotherapy alone provides limited benefit in this setting. Chemo-immunotherapy (CIT) has demonstrated favorable efficacy and safety profiles in lung cancer. Our pre-clinical study showed that i...

Descripción completa

Detalles Bibliográficos
Autores principales: Vera Aguilera, Jesus, Paludo, Jonas, McWilliams, Robert R., Zhang, Henan, Li, Ying, Kumar, Anagha B., Failing, Jarrett, Kottschade, Lisa A., Block, Matthew S., Markovic, Svetomir N., Dong, Haidong, Dronca, Roxana S., Yan, Yiyi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Lippincott Williams & Wilkins 2020
Materias:
Original Articles: Clinical research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7331824/
https://www.ncbi.nlm.nih.gov/pubmed/32404734
http://dx.doi.org/10.1097/CMR.0000000000000669

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7331824/
https://www.ncbi.nlm.nih.gov/pubmed/32404734
http://dx.doi.org/10.1097/CMR.0000000000000669

Ejemplares similares